Amphastar Pharmaceuticals (AMPH) Total Non-Current Liabilities (2014 - 2026)

Amphastar Pharmaceuticals' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $868.8 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 2.15% year-over-year to $868.8 million in Q1 2026; TTM through Mar 2026 was $868.8 million, a 2.15% increase from a year earlier, with the FY2025 full-year figure at $834.6 million, up 1.25% from the prior year.
• Total Non-Current Liabilities improved to $868.8 million in Q1 2026 per AMPH's latest filing, from $834.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $942.3 million in Q3 2023 and bottomed at $206.1 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $824.2 million (2024), against an average of $658.2 million.
• Across the five-year window, Total Non-Current Liabilities jumped 354.46% in 2023 and slipped 16.11% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $206.1 million in 2022, then jumped by 320.87% to $867.4 million in 2023, then slipped by 4.98% to $824.2 million in 2024, then gained by 1.25% to $834.6 million in 2025, then advanced by 4.11% to $868.8 million in 2026.
• Per Business Quant, the three latest AMPH Total Non-Current Liabilities figures stand at $868.8 million (Q1 2026), $834.6 million (Q4 2025), and $882.5 million (Q3 2025).